Jan 30, 2025, 17:32
Ahmed Kotb: Bispecific Antibodies vs. CAR-T for Relapsed/Refractory Follicular Lymphoma
Ahmed Kotb, Hematologist and Bone marrow transplanter at King Faisal Specialist Hospital International Holding Company, shared a post on X:
“Bispecific Antibodies vs. CAR-T for Relapsed/Refractory Follicular Lymphoma
BsAb
Off-the-shelf, outpatient, low toxicity
Possible indefinite treatment
CAR-T
Very high CR, long PFS, curative potential
Neurotoxicity risk,long wait time.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 30, 2025, 17:14
Jan 30, 2025, 17:01
Jan 30, 2025, 15:37
Jan 30, 2025, 15:24
Jan 30, 2025, 15:16